MSMichael Seimetz

Michael Seimetz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Seimetz has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Pichl

    Justus-Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany

    2 shared publications
  • Andreas Günther

    Center for Interstitial and Rare Lung Diseases, Justus-Liebig-University, University of Giessen and Marburg Lung Center, Member of the German Center for Lung Research, Giessen, Germany

    2 shared publications
  • Andreas Hecker

    Department of General, Visceral, Thoracic and Transplant Surgery, University Hospital Giessen, Justus-Liebig-University Giessen, Rudolf-Buchheim-Strasse 6, 35392 Giessen, Germany

    2 shared publications
  • Athanasios Fysikopoulos

    Justus-Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany

    2 shared publications
  • Baktybek Kojonazarov

    Justus-Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany

    2 shared publications
  • Cheng-Yu Wu

    Excellence Cluster Cardio-Pulmonary Institute (CPI), Institute for Lung Health (ILH), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus Liebig University (JLU), Giessen, Germany

    2 shared publications

Latest Publications

  • Open Access

    Author Correction: NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD

    by Michael Seimetz, Natascha Sommer, Mariola Bednorz, Oleg Pak, Christine Veith, Stefan Hadzic, Marija Gredic, Nirmal Parajuli, Baktybek Kojonazarov, Simone Kraut, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD

    by Michael Seimetz, Natascha Sommer, Mariola Bednorz, Oleg Pak, Christine Veith, Stefan Hadzic, Marija Gredic, Nirmal Parajuli, Baktybek Kojonazarov, Simone Kraut, et al.

    Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and death worldwide. Peroxynitrite, formed from nitric oxide, which is derived from inducible nitric oxide synthase, and superoxide, has been implicated in the development of emphysema, but the source of the superoxide was hitherto not characterized. Here, we identify the non-phagocytic NADPH oxidase organizer 1 (NOXO1) as the superoxide source and an essential driver of smoke-induced emphysema and pulmonary hypertension development in mice. NOXO1 is consistently upregulated in two models of lung emphysema, Cybb (also known as NADPH oxidase 2, Nox2)-knockout mice and wild-type mice with tobacco-smoke-induced emphysema, and in human COPD. Noxo1-knockout mice are protected against tobacco-smoke-induced pulmonary hypertension and emphysema. Quantification of superoxide, nitrotyrosine and multiple NOXO1-dependent signalling pathways confirm that peroxynitrite formation from nitric oxide and superoxide is a driver of lung emphysema. Our results suggest that NOXO1 may have potential as a therapeutic target in emphysema.